No Benefit From High-Dose Multivitamins Seen for HIV Patients Receiving Antiretroviral Therapy
 October 16- Boston, MA - Boston, MA - A new study
by Harvard School of Public Health (HSPH) researchers suggests that, for HIV patients receiving highly active antiretroviral therapy
(HAART) to treat HIV, there is no benefit from high- vs. standard-dose micronutrient supplementation-and that, in fact, high-dose
supplements may cause harm. The study is the first large randomized trial to look at how high-dose multivitamin supplementation
affects clinical outcomes among people on HAART.
The study appears in the October 17, 2012 issue of the Journal of the American Medical Association (JAMA).
The study appears in the October 17, 2012 issue of the Journal of the American Medical Association (JAMA).
Previous studies have shown that high doses of supplemental micronutrients help HIV patients who are not receiving HAART reduce disease
progression and death, thus prolonging the time before HAART initiation is needed. The HSPH researchers wanted to know if high-dose
multivitamin supplementation would provide a similar benefit for HIV patients on HAART; although HAART undoubtedly has major
benefits, recovery of the immune system is incomplete, and the risks of mortality and opportunistic infections remain high
especially in the first few months after HAART initiation.
The researchers, including lead author Sheila Isanaka ,
research fellow in the HSPH Department of Nutrition, and senior author Wafaie Fawzi , professor
of nutrition, epidemiology, and global health and chair of the Department of Global Health and Population at HSPH, studied a group of
3,418 patients with HIV who started HAART between November 2006 and November 2008 in seven clinics in Dar es Salaam, Tanzania. Half
of the patients received high doses of supplements including vitamin B complex, vitamin C, and vitamin E; the other half received
standard doses at the recommended dietary allowance level for a median duration of 15 months.
The results showed that high-dose supplementation had no effect on several key measures that reveal HIV disease progression-CD4 count,
plasma viral load, body mass index, or hemoglobin level concentration-and did not reduce death or disease progression risks for
HIV-infected patients. In addition, the researchers found that high doses of multivitamins increased patients' risk of having
elevated levels of ALT, an enzyme associated with liver problems and other serious conditions.
"Although the provision of high-dose vitamin supplements has been found safe and efficacious among HIV-infected patients not receiving
HAART, the results from this study show that the safety and efficacy of nutritional interventions in the context of potent combination
therapies such as HAART need to be further examined," said Fawzi.
"This study provides no clear evidence of a benefit of high-dose micronutrient supplementation compared to standard-dose supplementation
in adults receiving HAART, but it highlights the need for further research on how micronutrient supplements can be better positioned
alongside antiretroviral drugs to reduce morbidity and mortality due to HIV," said Isanaka.
Micronutrients are key factors in maintaining immune function and neutralizing oxidative stress, and future studies could examine whether
micronutrient supplements might be of benefit if they are offered with food, or given in lower doses, or given only after HIV patients have
acclimated to HAART therapy, she said.
Other HSPH authors included Donna Spiegelman ,
professor of epidemiologic methods in the Departments of Epidemiology and Biostatistics; James Okuma, biostatistician; and Chalamilla
Guerino, research associate in the Department of Global Health and Population.
Support for the study was provided by the National Institute of Child Health and Human Development (grant RO1 HD32257).
"Effect of High-Dose vs Standard-Dose Multivitamin Supplementation at the Initiation of HAART on HIV Disease Progression and Mortality in
Tanzania: A Randomized Controlled Trial," Sheila Isanaka, Ferdinand Mugusi, Claudia Hawkins, Donna Spiegelman, James Okuma, Said Aboud,
Chalamilla Guerino, and Wafaie Fawzi, JAMA, October 17, 2012, Vol. 208, No. 15
"Effect of High-Dose vs Standard-Dose Multivitamin Supplementation at the Initiation of HAART on HIV Disease Progression and Mortality
in Tanzania: A Randomized Controlled Trial," Sheila Isanaka, Ferdinand Mugusi, Claudia Hawkins, Donna Spiegelman, James Okuma, Said Aboud,
Chalamilla Guerino, and Wafaie Fawzi, JAMA, October 17, 2012, Vol. 208, No. 15
###
For more information:
Marge Dwyer
mhdwyer@hsph.harvard.edu
617.432.8416
photo: iStockphoto.com
Source: Harvard School of Public Healthhttp://www.hsph.harvard.edu/news/press-releases/2012-releases/multivitamins-hiv-antiretroviral-therapy.html
Harvard School of Public Health ( www.hsph.harvard.edu ) is dedicated to advancing the public's health through learning, discovery, and communication. More than 400 faculty members are engaged in teaching and training the 1,000-plus student body in a broad spectrum of disciplines crucial to the health and well being of individuals and populations around the world. Programs and projects range from the molecular biology of AIDS vaccines to the epidemiology of cancer; from risk analysis to violence prevention; from maternal and children's health to quality of care measurement; from health care management to international health and human rights. For more information on the school visit: http://www.hsph.harvard.edu .
Twitter: www.twitter.com/HarvardHSPH
Facebook: www.facebook.com/harvardpublichealth
You Tube: www.youtube.com/user/HarvardPublicHealth
Website: www.hsph.harvard.edu
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News
|
